International Journal of Colorectal Disease

, Volume 22, Issue 4, pp 429–437 | Cite as

Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease

  • Renata D’IncàEmail author
  • Elisabetta Dal Pont
  • Vincenza Di Leo
  • Antonio Ferronato
  • Walter Fries
  • Maria Grazia Vettorato
  • Diego Martines
  • Giacomo Carlo Sturniolo
Original Article


Background and aims

Calprotectin and lactoferrin are specific neutrophil-derived proteins, which can be measured in the feces because they are released by cells in inflammatory conditions. We evaluated the efficacy of calprotectin and lactoferrin in detecting organic disease as assessed by colonoscopy.


The study comprised 144 patients undergoing colonoscopy for lower gastrointestinal symptoms (abdominal pain, altered bowel habits, and bloody stools) (67), or inflammatory bowel disease activity, or surveillance for dysplasia (77). A single stool sample was assayed for calprotectin and lactoferrin. The proportion of patients correctly diagnosed with each test and the relationship with endoscopic and histological findings were measured.


Fecal excretion of calprotectin significantly correlated with the finding of colonic inflammation at endoscopy, both in ulcerative colitis and in Crohn’s disease (p<0,001 and p<0,008, respectively), while lactoferrin excretion significantly correlated with histological inflammation (p=0.001 and p=0.009 respectively). Recommended cut-off values need to be adjusted in the inflammatory bowel disease group. Overall sensitivity, specificity, positive predictive value, and diagnostic efficacy were 78, 83, 86, and 80% for calprotectin and 80, 85, 87, and 81% for lactoferrin, respectively.


Fecal calprotectin and lactoferrin appear to be equally recommendable as inflammatory disease markers in patients with lower gastrointestinal symptoms. Both tests are needed to accurately discriminate activity in inflammatory bowel disease patients.


Calprotectin Colon cancer Crohn’s disease Lactoferrin Ulcerative colitis 



Dr. R. D’Incà and Dr. E. Dal Pont contributed equally to this work. This is supported in part by a grant from MIUR ex 40% 2004 (2004063577_004).


  1. 1.
    Poullis A, Foster R, Mendall MA, Fagerhol MK (2003) Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol 18(7):756–762PubMedCrossRefGoogle Scholar
  2. 2.
    Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB (2003) Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 98(6):1309–1314PubMedCrossRefGoogle Scholar
  3. 3.
    Guerrant RL, Araujo V, Soares E, Kotloff K, Lima AA, Cooper WH, Lee AG (1992) Measurement of fecal lactoferrin as a marker of fecal leukocytes. J Clin Microbiol 30(5):1238–1242PubMedGoogle Scholar
  4. 4.
    Martins CA, Fonteles MG, Barrett LJ, Guerrant RL (1995) Correlation of lactoferrin with neutrophilic inflammation in body fluids. Clin Diagn Lab Immunol 2(6):763–765PubMedGoogle Scholar
  5. 5.
    Sugi K, Saitoh O, Hirata I, Katsu K (1996) Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 91(5):927–934PubMedGoogle Scholar
  6. 6.
    Voganatsi A, Panyutich A, Miyasaki KT, Murthy RK (2001) Mechanism of extracellular release of human neutrophil calprotectin complex. J Leukoc Biol 70:130–134PubMedGoogle Scholar
  7. 7.
    Kayazawa M, Saitoh O, Kojima K, Nakagawa K, Tanaka S, Tabata K, Matsuse R, Uchida K, Hoshimoto M, Hirata I, Katsu K (2002) Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 97(2):360–369PubMedCrossRefGoogle Scholar
  8. 8.
    Roseth AG, Fagerhol MK, Aadland E, Schjonsby H (1992) Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 27(9):793–798PubMedGoogle Scholar
  9. 9.
    Fine KD, Ogunji F, George J, Niehaus MD, Guerrant RL (1998) Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea. Am J Gastroenterol 93(8):1300–1305PubMedCrossRefGoogle Scholar
  10. 10.
    Gaya DR, Lyon TDB, Duncan A, Neilly JB, Han S, Howell J, Liddell C, Stanley AJ, Morris AJ, Mackenzie JF (2005) Fecal calprotectin in the assessment of Crohn’s disease activity. Q J Med 98:435–441Google Scholar
  11. 11.
    Summerton CB, Longlands MG, Wiener K, Shreeve DR (2002) Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 14(8):841–845PubMedCrossRefGoogle Scholar
  12. 12.
    Saitoh O, Kojima K, Kayazawa M, Sugi K, Tanaka S, Nakagawa K, Teranishi T, Matsuse R, Uchida K, Morikawa H, Hirata I, Katsu K (2000) Comparison of tests for fecal lactoferrin and fecal occult blood for colorectal diseases: a prospective pilot study. Intern Med 39(10):778–782PubMedGoogle Scholar
  13. 13.
    Silberer H, Kuppers B, Mickisch O, Baniewicz W, Drescher M, Traber L, Kempf A, Schmidt-Gayk H (2005) Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab 51(3–4):117–126PubMedGoogle Scholar
  14. 14.
    Langhorst J, Elsenbruch S, Mueller T, Rueffer A, Spahn G, Michalsen A, Dobos GJ (2005) Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 11(12):1085–1091PubMedCrossRefGoogle Scholar
  15. 15.
    Larsen A, Hovdenak N, Karlsdottir A, Wentzel-Larsen T, Dahl O, Fagerhol MK (2004) Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a pilot study of eight stool markers. Scand J Gastroenterol 30:1113–1118CrossRefGoogle Scholar
  16. 16.
    Schroeder KW, Tremaine WJ, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 317:1625–1629PubMedCrossRefGoogle Scholar
  17. 17.
    Floren CH, Benton C, Willen R (1987) Histological and colonoscopy assessment of disease extension in ulcerative colitis. Scand J Gastroenterol 22:459–462PubMedGoogle Scholar
  18. 18.
    Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P (2004) Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 60:505–512PubMedCrossRefGoogle Scholar
  19. 19.
    Fazio VW, Marchetti F, Church JM, Goldblum JR, Lavery C, Hull TL, Milsom JW, Strong SA, Oakley JR, Secic M (1996) Effect of resection margins on the recurrence of Crohn’s disease in the small bowel. Ann Surg 224:563–567PubMedCrossRefGoogle Scholar
  20. 20.
    Limburg PJ, Ahlquist DA, Sandborn WJ, Mahoney DW, Devens ME, Harrington JJ, Zinsmeister AR (2000) Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 95(10):2831–2837PubMedCrossRefGoogle Scholar
  21. 21.
    Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F, Scalici C, Montalto G, Di Fede G, Rini G, Notarbartolo A, Averna MR (2003) Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 49:861–867PubMedCrossRefGoogle Scholar
  22. 22.
    Kapel N (2004) Faecal inflammatory markers in nutrition and digestive diseases in children. Arch Pediatr 11(5):403–405PubMedCrossRefGoogle Scholar
  23. 23.
    Roseth AG, Schmidt PN, Fagerhol MK (1999) Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 34(1):50–54PubMedCrossRefGoogle Scholar
  24. 24.
    Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT (1992) Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339:89–91PubMedCrossRefGoogle Scholar
  25. 25.
    Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I (2001) Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 49(3):402–408PubMedCrossRefGoogle Scholar
  26. 26.
    Kristjansson J, Armbruster CH, Ugstad M, Kriwanek S, Nygaard K, Ton H, Fuglerud P (2001) Fecal excretion of calprotectin in colorectal cancer: relationship to tumor characteristics. Scand J Gastroenterol 36(2):202–207Google Scholar
  27. 27.
    Roseth AG, Kristjansson J, Fagerhol MK, Schjonsby H, Aadland E, Nygaard K, Roald B (1993) Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 28(12):1073–1076PubMedGoogle Scholar
  28. 28.
    Poullis A, Foster R, Shetty A, Fagerhol MK, Mendal MM (2004) Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomark Prev 13:279–284CrossRefGoogle Scholar
  29. 29.
    Kronborg O, Ugstad M, Fuglerud P, Johne B, Hardcastle J, Scholefield JH, Vellacott K, Moshakis V, Reynolds JR (2000) Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 46(6):795–800PubMedCrossRefGoogle Scholar
  30. 30.
    Buderus S, Boone J, Lyerly D, Lentze MJ (2004) Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig Dis Sci 49(6):1036–1039PubMedCrossRefGoogle Scholar
  31. 31.
    Roseth AG, Aadland E, Jahnsen J, Raknerud N (1997) Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 58(2):176–180PubMedCrossRefGoogle Scholar
  32. 32.
    Hanai H, Takeuchi K, Iida T, Kashiwagi N, Saniabadi AR, Matsushita I, Sato Y, Kasuga N, Nakamura T (2004) Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig Dis Sci 49(9):1438–1443PubMedCrossRefGoogle Scholar
  33. 33.
    Tibble JA, Sighthorsson G, Bridger S, Fagerhol MK, Bjarnason I (2000) Surrogate markers on intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119:15–22PubMedCrossRefGoogle Scholar
  34. 34.
    Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, Ricchiuti A, Marchi S, Bottai M (2005) Calprotectin is a strong predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut 54:364–368PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Renata D’Incà
    • 1
    • 3
    Email author
  • Elisabetta Dal Pont
    • 1
  • Vincenza Di Leo
    • 1
  • Antonio Ferronato
    • 1
  • Walter Fries
    • 2
  • Maria Grazia Vettorato
    • 1
  • Diego Martines
    • 1
  • Giacomo Carlo Sturniolo
    • 1
  1. 1.Department of Surgical and Gastroenterological SciencesUniversity of PaduaPadovaItaly
  2. 2.Department of Internal Medicine and Medical TherapyUniversity of MessinaMessinaItaly
  3. 3.Divisione di GastroenterologiaOspedale CivilePadovaItaly

Personalised recommendations